ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

Bruna Pellini; Aadel A Chaudhuri

doi:10.1158/1078-0432.CCR-23-0420

ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

Clin Cancer Res. 2023 Jun 13;29(12):2176-2178. doi: 10.1158/1078-0432.CCR-23-0420.

Authors

Bruna Pellini^{1

2}, Aadel A Chaudhuri^{3

4

5

6

7

8}

Affiliations

¹ Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida.
³ Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
⁴ Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri.
⁵ Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
⁶ Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri.
⁷ Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, Missouri.
⁸ Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri.

Abstract

Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes. See related article by Sivapalan et al., p. 2310.

Publication types

Editorial
Comment

MeSH terms

Biomarkers, Tumor / genetics
Cell-Free Nucleic Acids*
Circulating Tumor DNA* / genetics
Humans
Lung Neoplasms* / genetics
Mutation
Small Cell Lung Carcinoma*

Substances

Cell-Free Nucleic Acids
Circulating Tumor DNA
Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding